HEARTFLOW BCG MATRIX TEMPLATE RESEARCH
Download Your Competitive Advantage
HeartFlow's BCG Matrix preview shows how its core diagnostic products map to market growth and share, highlighting potential Stars in AI-driven cardiovascular imaging and Question Marks where investment could pay off; the full report gives precise quadrant placements, revenue and market-share data, and actionable moves to optimize portfolio returns. Purchase the full BCG Matrix for a complete Word report plus an editable Excel summary that speeds decision-making and guides capital allocation with confidence.
Stars
HeartFlow FFRCT Analysis
HeartFlow FFRCT Analysis is the flagship product, driving 98% of HeartFlow's revenue as of mid-2025 and generating the vast majority of the company's $235 million FY2025 revenue run rate.
It holds a 40-45% global market share in FFR-CT software, backed by first-mover advantage and 600+ peer-reviewed papers supporting clinical adoption.
Integration spans 1,465 U.S. hospital accounts as of early 2026, underpinning durable commercial scale and high-margin service revenue.
U.S. Commercial Market Expansion
U.S. Commercial Market Expansion: HeartFlow's U.S. revenue grew 42% YoY to $42.5 million in Q3 2025, positioning the company as a Star with aggressive scaling after its August 2025 IPO (85.2 million shares, $2.03 billion market cap).
AI-Enabled Plaque Analysis Platform
The AI-Enabled Plaque Analysis Platform, FDA-cleared in September 2025, is a Star entering rapid adoption with 21% better plaque detection vs. Gen‑1 and 95% concordance with intravascular ultrasound (IVUS).
Central to HeartFlow's second-wave growth, it targets a $1.7 billion incremental market and underpins revenue expansion as utilization scales in 2026-2027.
UnitedHealthcare and Cigna Coverage
UnitedHealthcare and Cigna activated nationwide coverage for HeartFlow's Plaque Analysis on October 1, 2025, unlocking payor access to ~57% of U.S. covered lives and driving projected 2026 procedure volume growth of 120-180% versus 2025.
This reimbursement shift moves Plaque Analysis from niche to standard in the CCTA pathway, supporting revenue upside: estimated incremental 2026 revenue of $95-$140 million based on 2025 ASPs and utilization trends.
- Coverage live: Oct 1, 2025
- Payor reach: ~57% of U.S. relevant lives
- Projected 2026 volume growth: 120-180%
- Estimated incremental 2026 revenue: $95-$140M
Integrated HeartFlow One Platform
HeartFlow One unifies RoadMap, FFRct, and Plaque Analysis into a market-leading ecosystem used by >1,400 institutions, creating high switching costs and recurring revenue-HeartFlow reported 2025 revenue of $158.6M, up 28% YoY, reflecting platform uptake.
The non-invasive platform sustains a moat vs hardware diagnostics and drove medical management changes in >50% of patients in the DECIDE registry, strengthening referral and reimbursement traction.
- Installed base: >1,400 institutions (global)
- 2025 revenue: $158.6M (+28% YoY)
- DECIDE: >50% patients had management change
- High switching costs: integrated workflow + recurring fees
HeartFlow surges: $235M run rate, 40-45% FFRct share, $95-$140M 2026 upside
HeartFlow's FFRct and Plaque Analysis are Stars: FY2025 revenue $235M run rate (FFRct 98%), 40-45% FFRct share, 1,465 U.S. hospitals, 2025 revenue $158.6M (+28%), Plaque Analysis FDA-cleared Sep 2025, payor reach ~57% (coverage Oct 1, 2025), projected 2026 incremental revenue $95-$140M.
| Metric | 2025/2026 |
|---|---|
| Run rate revenue | $235M (FY2025) |
| FFRct share | 40-45% |
| Installed U.S. hospitals | 1,465 |
| Reported 2025 revenue | $158.6M (+28%) |
| Payor reach | ~57% |
| Projected 2026 incremental | $95-$140M |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix review of HeartFlow's portfolio with strategic actions for Stars, Cash Cows, Question Marks, and Dogs.
Customizable Excel Spreadsheet
One-page HeartFlow BCG Matrix placing units in quadrants for quick C-suite decisions and presentations
Cash Cows
Core FFRCT Subscription Revenue
Core FFRCT Subscription Revenue is HeartFlow's reliable cash cow, posting gross margins of 76.5% in Q3 2025 and management projecting >80% by 2026; recurring subscriptions generated $210M revenue in FY2025, funding R&D for new AI products.
U.K. NHS Partnership
The U.K. NHS Partnership is a stable cash cow for HeartFlow, live in nearly 100 hospitals as of 2025 and generating predictable revenue; the FISH&CHIPS study reported per-patient savings of £1,042, supporting long-term contract renewals.
Proprietary Imaging Dataset
HeartFlow's proprietary imaging library of 110+ million annotated coronary CTA scans (2025) is a low-maintenance, high-margin asset that consistently fuels model training and cuts new diagnostic development costs by an estimated 30-40% versus de novo datasets.
The dataset underpins all AI pipelines, acts as a durable intellectual-property cash cow with multi-year utility, and creates a high replication barrier-supporting HeartFlow's sustained technical lead and recurring software revenue.
Institutional Installed Base
Institutional Installed Base: HeartFlow serves over 1,465 active U.S. accounts (2025), shifting sales from hunting to farming and reducing new acquisition cost per account by ~40% versus peers.
Top-tier cardiovascular centers enable low-cost cross-sell of new modules; incremental revenue per installed account averages $26k annually in 2025.
The network effect drives ~220k diagnostic cases through HeartFlow's cloud analysis in 2025, providing predictable revenue and higher lifetime value.
- 1,465+ active U.S. accounts (2025)
- $26,000 incremental revenue per account (2025)
- ~220,000 diagnostic cases processed (2025)
- ~40% lower acquisition cost vs. peers
Public Market Capitalization
HeartFlow's August 2025 IPO raised $364.2 million and, after retiring $115 million of debt in 2025, left the company debt-free with $291.2 million cash as of September 30, 2025, enabling self-funded growth from its market leadership.
- IPO proceeds: $364.2M
- Debt eliminated: $115M
- Cash on hand (9/30/2025): $291.2M
- Net cash position: $291.2M
Impressive 2025: $210M FFRCT, 76.5% GM, 110M scans, 1,465 US accounts, $291M cash
Core FFRCT subs: $210M FY2025, 76.5% gross margin (Q3 2025); UK NHS: ~100 hospitals, £1,042 per-patient savings (FISH&CHIPS); Imaging library: 110M+ scans (2025), cuts dev cost 30-40%; Installed base: 1,465 US accounts, $26k incremental/account, ~220k cases (2025); IPO cash: $291.2M (9/30/2025).
| Metric | 2025 Value |
|---|---|
| FFRCT Revenue | $210M |
| Gross Margin (Q3) | 76.5% |
| UK Hospitals | ~100 |
| Imaging Library | 110M+ scans |
| US Accounts | 1,465+ |
| Incremental Rev/Account | $26,000 |
| Cases Processed | ~220,000 |
| Cash on Hand | $291.2M (9/30/2025) |
Preview = Final Product
HeartFlow BCG Matrix
The file you're previewing is the exact HeartFlow BCG Matrix report you'll receive after purchase-fully formatted, professional, and free of watermarks or demo content for immediate use.
This preview mirrors the final deliverable: a market-informed BCG Matrix crafted for strategic clarity, ready to download and share with your team or clients without tweaks.
Upon purchase you'll get the same editable, print-ready document shown here-designed by strategy experts for seamless integration into presentations and planning.
No placeholders or surprises: what you see is the report that will be delivered to your inbox after a one-time purchase.
HEARTFLOW BCG MATRIX TEMPLATE RESEARCH
Download Your Competitive Advantage
HeartFlow's BCG Matrix preview shows how its core diagnostic products map to market growth and share, highlighting potential Stars in AI-driven cardiovascular imaging and Question Marks where investment could pay off; the full report gives precise quadrant placements, revenue and market-share data, and actionable moves to optimize portfolio returns. Purchase the full BCG Matrix for a complete Word report plus an editable Excel summary that speeds decision-making and guides capital allocation with confidence.
Stars
HeartFlow FFRCT Analysis
HeartFlow FFRCT Analysis is the flagship product, driving 98% of HeartFlow's revenue as of mid-2025 and generating the vast majority of the company's $235 million FY2025 revenue run rate.
It holds a 40-45% global market share in FFR-CT software, backed by first-mover advantage and 600+ peer-reviewed papers supporting clinical adoption.
Integration spans 1,465 U.S. hospital accounts as of early 2026, underpinning durable commercial scale and high-margin service revenue.
U.S. Commercial Market Expansion
U.S. Commercial Market Expansion: HeartFlow's U.S. revenue grew 42% YoY to $42.5 million in Q3 2025, positioning the company as a Star with aggressive scaling after its August 2025 IPO (85.2 million shares, $2.03 billion market cap).
AI-Enabled Plaque Analysis Platform
The AI-Enabled Plaque Analysis Platform, FDA-cleared in September 2025, is a Star entering rapid adoption with 21% better plaque detection vs. Gen‑1 and 95% concordance with intravascular ultrasound (IVUS).
Central to HeartFlow's second-wave growth, it targets a $1.7 billion incremental market and underpins revenue expansion as utilization scales in 2026-2027.
UnitedHealthcare and Cigna Coverage
UnitedHealthcare and Cigna activated nationwide coverage for HeartFlow's Plaque Analysis on October 1, 2025, unlocking payor access to ~57% of U.S. covered lives and driving projected 2026 procedure volume growth of 120-180% versus 2025.
This reimbursement shift moves Plaque Analysis from niche to standard in the CCTA pathway, supporting revenue upside: estimated incremental 2026 revenue of $95-$140 million based on 2025 ASPs and utilization trends.
- Coverage live: Oct 1, 2025
- Payor reach: ~57% of U.S. relevant lives
- Projected 2026 volume growth: 120-180%
- Estimated incremental 2026 revenue: $95-$140M
Integrated HeartFlow One Platform
HeartFlow One unifies RoadMap, FFRct, and Plaque Analysis into a market-leading ecosystem used by >1,400 institutions, creating high switching costs and recurring revenue-HeartFlow reported 2025 revenue of $158.6M, up 28% YoY, reflecting platform uptake.
The non-invasive platform sustains a moat vs hardware diagnostics and drove medical management changes in >50% of patients in the DECIDE registry, strengthening referral and reimbursement traction.
- Installed base: >1,400 institutions (global)
- 2025 revenue: $158.6M (+28% YoY)
- DECIDE: >50% patients had management change
- High switching costs: integrated workflow + recurring fees
HeartFlow surges: $235M run rate, 40-45% FFRct share, $95-$140M 2026 upside
HeartFlow's FFRct and Plaque Analysis are Stars: FY2025 revenue $235M run rate (FFRct 98%), 40-45% FFRct share, 1,465 U.S. hospitals, 2025 revenue $158.6M (+28%), Plaque Analysis FDA-cleared Sep 2025, payor reach ~57% (coverage Oct 1, 2025), projected 2026 incremental revenue $95-$140M.
| Metric | 2025/2026 |
|---|---|
| Run rate revenue | $235M (FY2025) |
| FFRct share | 40-45% |
| Installed U.S. hospitals | 1,465 |
| Reported 2025 revenue | $158.6M (+28%) |
| Payor reach | ~57% |
| Projected 2026 incremental | $95-$140M |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix review of HeartFlow's portfolio with strategic actions for Stars, Cash Cows, Question Marks, and Dogs.
Customizable Excel Spreadsheet
One-page HeartFlow BCG Matrix placing units in quadrants for quick C-suite decisions and presentations
Cash Cows
Core FFRCT Subscription Revenue
Core FFRCT Subscription Revenue is HeartFlow's reliable cash cow, posting gross margins of 76.5% in Q3 2025 and management projecting >80% by 2026; recurring subscriptions generated $210M revenue in FY2025, funding R&D for new AI products.
U.K. NHS Partnership
The U.K. NHS Partnership is a stable cash cow for HeartFlow, live in nearly 100 hospitals as of 2025 and generating predictable revenue; the FISH&CHIPS study reported per-patient savings of £1,042, supporting long-term contract renewals.
Proprietary Imaging Dataset
HeartFlow's proprietary imaging library of 110+ million annotated coronary CTA scans (2025) is a low-maintenance, high-margin asset that consistently fuels model training and cuts new diagnostic development costs by an estimated 30-40% versus de novo datasets.
The dataset underpins all AI pipelines, acts as a durable intellectual-property cash cow with multi-year utility, and creates a high replication barrier-supporting HeartFlow's sustained technical lead and recurring software revenue.
Institutional Installed Base
Institutional Installed Base: HeartFlow serves over 1,465 active U.S. accounts (2025), shifting sales from hunting to farming and reducing new acquisition cost per account by ~40% versus peers.
Top-tier cardiovascular centers enable low-cost cross-sell of new modules; incremental revenue per installed account averages $26k annually in 2025.
The network effect drives ~220k diagnostic cases through HeartFlow's cloud analysis in 2025, providing predictable revenue and higher lifetime value.
- 1,465+ active U.S. accounts (2025)
- $26,000 incremental revenue per account (2025)
- ~220,000 diagnostic cases processed (2025)
- ~40% lower acquisition cost vs. peers
Public Market Capitalization
HeartFlow's August 2025 IPO raised $364.2 million and, after retiring $115 million of debt in 2025, left the company debt-free with $291.2 million cash as of September 30, 2025, enabling self-funded growth from its market leadership.
- IPO proceeds: $364.2M
- Debt eliminated: $115M
- Cash on hand (9/30/2025): $291.2M
- Net cash position: $291.2M
Impressive 2025: $210M FFRCT, 76.5% GM, 110M scans, 1,465 US accounts, $291M cash
Core FFRCT subs: $210M FY2025, 76.5% gross margin (Q3 2025); UK NHS: ~100 hospitals, £1,042 per-patient savings (FISH&CHIPS); Imaging library: 110M+ scans (2025), cuts dev cost 30-40%; Installed base: 1,465 US accounts, $26k incremental/account, ~220k cases (2025); IPO cash: $291.2M (9/30/2025).
| Metric | 2025 Value |
|---|---|
| FFRCT Revenue | $210M |
| Gross Margin (Q3) | 76.5% |
| UK Hospitals | ~100 |
| Imaging Library | 110M+ scans |
| US Accounts | 1,465+ |
| Incremental Rev/Account | $26,000 |
| Cases Processed | ~220,000 |
| Cash on Hand | $291.2M (9/30/2025) |
Preview = Final Product
HeartFlow BCG Matrix
The file you're previewing is the exact HeartFlow BCG Matrix report you'll receive after purchase-fully formatted, professional, and free of watermarks or demo content for immediate use.
This preview mirrors the final deliverable: a market-informed BCG Matrix crafted for strategic clarity, ready to download and share with your team or clients without tweaks.
Upon purchase you'll get the same editable, print-ready document shown here-designed by strategy experts for seamless integration into presentations and planning.
No placeholders or surprises: what you see is the report that will be delivered to your inbox after a one-time purchase.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Download Your Competitive Advantage
HeartFlow's BCG Matrix preview shows how its core diagnostic products map to market growth and share, highlighting potential Stars in AI-driven cardiovascular imaging and Question Marks where investment could pay off; the full report gives precise quadrant placements, revenue and market-share data, and actionable moves to optimize portfolio returns. Purchase the full BCG Matrix for a complete Word report plus an editable Excel summary that speeds decision-making and guides capital allocation with confidence.
Stars
HeartFlow FFRCT Analysis
HeartFlow FFRCT Analysis is the flagship product, driving 98% of HeartFlow's revenue as of mid-2025 and generating the vast majority of the company's $235 million FY2025 revenue run rate.
It holds a 40-45% global market share in FFR-CT software, backed by first-mover advantage and 600+ peer-reviewed papers supporting clinical adoption.
Integration spans 1,465 U.S. hospital accounts as of early 2026, underpinning durable commercial scale and high-margin service revenue.
U.S. Commercial Market Expansion
U.S. Commercial Market Expansion: HeartFlow's U.S. revenue grew 42% YoY to $42.5 million in Q3 2025, positioning the company as a Star with aggressive scaling after its August 2025 IPO (85.2 million shares, $2.03 billion market cap).
AI-Enabled Plaque Analysis Platform
The AI-Enabled Plaque Analysis Platform, FDA-cleared in September 2025, is a Star entering rapid adoption with 21% better plaque detection vs. Gen‑1 and 95% concordance with intravascular ultrasound (IVUS).
Central to HeartFlow's second-wave growth, it targets a $1.7 billion incremental market and underpins revenue expansion as utilization scales in 2026-2027.
UnitedHealthcare and Cigna Coverage
UnitedHealthcare and Cigna activated nationwide coverage for HeartFlow's Plaque Analysis on October 1, 2025, unlocking payor access to ~57% of U.S. covered lives and driving projected 2026 procedure volume growth of 120-180% versus 2025.
This reimbursement shift moves Plaque Analysis from niche to standard in the CCTA pathway, supporting revenue upside: estimated incremental 2026 revenue of $95-$140 million based on 2025 ASPs and utilization trends.
- Coverage live: Oct 1, 2025
- Payor reach: ~57% of U.S. relevant lives
- Projected 2026 volume growth: 120-180%
- Estimated incremental 2026 revenue: $95-$140M
Integrated HeartFlow One Platform
HeartFlow One unifies RoadMap, FFRct, and Plaque Analysis into a market-leading ecosystem used by >1,400 institutions, creating high switching costs and recurring revenue-HeartFlow reported 2025 revenue of $158.6M, up 28% YoY, reflecting platform uptake.
The non-invasive platform sustains a moat vs hardware diagnostics and drove medical management changes in >50% of patients in the DECIDE registry, strengthening referral and reimbursement traction.
- Installed base: >1,400 institutions (global)
- 2025 revenue: $158.6M (+28% YoY)
- DECIDE: >50% patients had management change
- High switching costs: integrated workflow + recurring fees
HeartFlow surges: $235M run rate, 40-45% FFRct share, $95-$140M 2026 upside
HeartFlow's FFRct and Plaque Analysis are Stars: FY2025 revenue $235M run rate (FFRct 98%), 40-45% FFRct share, 1,465 U.S. hospitals, 2025 revenue $158.6M (+28%), Plaque Analysis FDA-cleared Sep 2025, payor reach ~57% (coverage Oct 1, 2025), projected 2026 incremental revenue $95-$140M.
| Metric | 2025/2026 |
|---|---|
| Run rate revenue | $235M (FY2025) |
| FFRct share | 40-45% |
| Installed U.S. hospitals | 1,465 |
| Reported 2025 revenue | $158.6M (+28%) |
| Payor reach | ~57% |
| Projected 2026 incremental | $95-$140M |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix review of HeartFlow's portfolio with strategic actions for Stars, Cash Cows, Question Marks, and Dogs.
Customizable Excel Spreadsheet
One-page HeartFlow BCG Matrix placing units in quadrants for quick C-suite decisions and presentations
Cash Cows
Core FFRCT Subscription Revenue
Core FFRCT Subscription Revenue is HeartFlow's reliable cash cow, posting gross margins of 76.5% in Q3 2025 and management projecting >80% by 2026; recurring subscriptions generated $210M revenue in FY2025, funding R&D for new AI products.
U.K. NHS Partnership
The U.K. NHS Partnership is a stable cash cow for HeartFlow, live in nearly 100 hospitals as of 2025 and generating predictable revenue; the FISH&CHIPS study reported per-patient savings of £1,042, supporting long-term contract renewals.
Proprietary Imaging Dataset
HeartFlow's proprietary imaging library of 110+ million annotated coronary CTA scans (2025) is a low-maintenance, high-margin asset that consistently fuels model training and cuts new diagnostic development costs by an estimated 30-40% versus de novo datasets.
The dataset underpins all AI pipelines, acts as a durable intellectual-property cash cow with multi-year utility, and creates a high replication barrier-supporting HeartFlow's sustained technical lead and recurring software revenue.
Institutional Installed Base
Institutional Installed Base: HeartFlow serves over 1,465 active U.S. accounts (2025), shifting sales from hunting to farming and reducing new acquisition cost per account by ~40% versus peers.
Top-tier cardiovascular centers enable low-cost cross-sell of new modules; incremental revenue per installed account averages $26k annually in 2025.
The network effect drives ~220k diagnostic cases through HeartFlow's cloud analysis in 2025, providing predictable revenue and higher lifetime value.
- 1,465+ active U.S. accounts (2025)
- $26,000 incremental revenue per account (2025)
- ~220,000 diagnostic cases processed (2025)
- ~40% lower acquisition cost vs. peers
Public Market Capitalization
HeartFlow's August 2025 IPO raised $364.2 million and, after retiring $115 million of debt in 2025, left the company debt-free with $291.2 million cash as of September 30, 2025, enabling self-funded growth from its market leadership.
- IPO proceeds: $364.2M
- Debt eliminated: $115M
- Cash on hand (9/30/2025): $291.2M
- Net cash position: $291.2M
Impressive 2025: $210M FFRCT, 76.5% GM, 110M scans, 1,465 US accounts, $291M cash
Core FFRCT subs: $210M FY2025, 76.5% gross margin (Q3 2025); UK NHS: ~100 hospitals, £1,042 per-patient savings (FISH&CHIPS); Imaging library: 110M+ scans (2025), cuts dev cost 30-40%; Installed base: 1,465 US accounts, $26k incremental/account, ~220k cases (2025); IPO cash: $291.2M (9/30/2025).
| Metric | 2025 Value |
|---|---|
| FFRCT Revenue | $210M |
| Gross Margin (Q3) | 76.5% |
| UK Hospitals | ~100 |
| Imaging Library | 110M+ scans |
| US Accounts | 1,465+ |
| Incremental Rev/Account | $26,000 |
| Cases Processed | ~220,000 |
| Cash on Hand | $291.2M (9/30/2025) |
Preview = Final Product
HeartFlow BCG Matrix
The file you're previewing is the exact HeartFlow BCG Matrix report you'll receive after purchase-fully formatted, professional, and free of watermarks or demo content for immediate use.
This preview mirrors the final deliverable: a market-informed BCG Matrix crafted for strategic clarity, ready to download and share with your team or clients without tweaks.
Upon purchase you'll get the same editable, print-ready document shown here-designed by strategy experts for seamless integration into presentations and planning.
No placeholders or surprises: what you see is the report that will be delivered to your inbox after a one-time purchase.
